Sglt2 Inhibitor
FDA approves first triple combination pill for type 2 diabetes
The FDA on Monday approved the first oral therapy to combine three type 2 diabetes medications into one pill: the SGLT2 inhibitor empagliflozin, the DPP-IV inhibitor linagliptin and metformin hydrochloride extended release, according to a press release from Boehringer Ingelheim and Eli Lilly and Co.
Diabetes and the heart: Top news of 2019
Dapagliflozin may improve lung fluid volume in HF
PHILADELPHIA — Treatment with the SGLT2 inhibitor dapagliflozin was not associated with a reduction in mean lung fluid volume among adults with HF with reduced ejection fraction compared with placebo.
2019: To close out a decade of progress, new ways of thinking about cardiology emerge
This interesting year was a fitting conclusion to an exciting decade. The Top 10 Stories of the Year in cardiology, selected by the Cardiology Today Editorial Board, represent well the changing landscape in our field.
SGLT2 inhibitors may lower gout risk
Among patients with type 2 diabetes, using SGLT2 inhibitors may lower the risk for gout compared with other antidiabetic medications, according to study findings published in the Annals of Internal Medicine.
Top HF news of 2019: A paradigm shift in pharmacotherapy
Healio and Cardiology Today present a list of the most-read articles related to HF and transplantation published in 2019. Readers were most interested in new data that show benefit of SGLT2 inhibition in patients with HF, even in the absence of diabetes; sacubitril/valsartan for HF with preserved ejection fraction, sex-specific prevention and more.
FDA grants priority review to dapagliflozin for HFrEF treatment
AstraZeneca announced that the SGLT2 inhibitor dapagliflozin has been granted priority review from the FDA to reduce the risk for CV mortality or worsening HF in patients with HF with reduced ejection fraction with and without type 2 diabetes.
DAPA-HF, REWIND, other cardiometabolic science highlighted at CMHC
CHICAGO — Healio presents live updates from the late-breaking trials session at the Cardiometabolic Health Congress.
VIDEO: Top takeaways from ESC Congress with Deepak L. Bhatt, MD, MPH
PARIS — In this video exclusive, Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital, professor of medicine at Harvard Medical School and Cardiology Today Editorial Board Member, highlights “practice-changing” research presented at the 2019 European Society of Cardiology Congress.
Out of the loop: Augmenting diuresis with SGLT2 inhibitors in HF
SGLT2 inhibitors were first approved in 2013 for the treatment of type 2 diabetes. These agents act by blocking glucose and sodium reabsorption, thereby increasing glucose excretion.